Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis

“…Novel treatment regimens should be explored in this setting. In a study performed by Fukuizumi et al (15), 12 patients received second-line treatment with paclitaxel containing regimen again, the ORR of this challenge group was 50%, and there were no cases of AE-ILD. In contrast, Kakiuchi et al (14) found the risk of AE-ILD with paclitaxel in the later lines of treatment was twice that of first-line treatment and reached 15.2%, whereas no AE-ILD associated with S-1 was observed in the later lines of treatment.…”

“…Subgroup analysis demonstrated treatment regimens, lung function, and total AE-ILD rate had a significant correlation with 1-yOS rate. It is worth noting that several prospective studies had significantly higher 1-yOS rates than retrospective studies (13)(14)(15)(16), ranging from 51.4 to 61.1%. We found that patients included in the prospective studies had better median lung function status than patients in the retrospective studies (Table 1), and our subgroup analysis showed the difference in 1-yOS rate between studies with median lung function better and poorer was significant (56.0 vs. 29.0%, p < 0.001) ( Table 2).…”

“…The results of subgroup analysis showed that ORR was associated with treatment regimens, and heterogeneity was mainly generated in the paclitaxel group. After comparing six studies in the paclitaxel group, we found that patients receiving paclitaxel 100 mg/m 2 weekly had a higher ORR (15,23), 61 and 70%, respectively. In the remaining studies, patients received paclitaxel 60-70 mg/m 2 weekly had poor ORR.…”

“…Chemotherapy is still the main treatment regimen for NSCLC patients with preexisting ILD. A series of studies (13)(14)(15)(16)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39) have investigated the risk and benefit of chemotherapy for NSCLC-ILD; however, all of these studies are single-arm trials, and part of them have a small sample size. Therefore, it is necessary to summarize the existing data to provide a basis for future clinical studies.…”

“…Recently, several multicenter prospective clinical trials (13)(14)(15)(16) focusing on NSCLC patients with ILD have been published, and their results can improve the quality of evidence. We therefore conducted a meta-analysis to evaluate the efficacy and safety of chemotherapy in the first-line treatment of patients with NSCLC-ILD.…”